NCT07040566 2025-12-17
A Trial of Varenicline for E-cigarette Cessation
Yale University
Phase 2 Recruiting
Clinical Trials
11 trialsNCT02029001 2025-08-07
MOST plus
Centre Leon Berard
Phase 2 Recruiting
NCT03906292 2025-03-10
CMLXI
University of Jena
Phase 2 Active not recruiting
NCT04515979 2024-12-09
Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects
MedPacto, Inc.
Phase 2 Terminated
NCT05216237 2022-04-11
A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer
Affiliated Hospital of Qinghai University
Phase 2 Unknown
NCT01856283 2021-01-13
Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells
Niguarda Hospital
Phase 2 Completed
NCT04015024 2019-07-16
A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT00509821 2019-04-05
Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed Glioblastoma
Eli Lilly and Company
Phase 2 Completed
NCT01243346 2018-06-28
Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene
Arog Pharmaceuticals, Inc.
Phase 2 Completed
NCT02101684 2018-03-05
Greko II
Grupo EspaƱol de Tumores HuƩrfanos e Infrecuentes
Phase 2 Terminated
NCT00751205 2014-10-28
Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)
Bayer
Phase 2 Completed